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NeuroinﬂammationPersistent neuroinﬂammation is implicated in the pathogenesis of seizures and neuronal degeneration of tempo-
ral lobe epilepsy (TLE). Circulating level of inﬂammatory cytokines was determined during inter-ictal period of
25 non-operated and 10 patients (OP) submitted to anterior temporal lobectomy. OP patients showed marked
reduction of IL-1β, TNFα, MIP-1α, but not IL-6 and TGF-β1. Paired analysis done before and after lobectomy
showed reduction of inﬂammatory cytokines but increased TGF-β1 levels, and lack of seizures for more than
6 months. Maintenance of high TGF-β1 and IL-6 cytokines in both groups suggests a role in down-regulation
of neuroinﬂammation and promotion of brain tissue remodeling for neuronal reorganization.
© 2012 Elsevier B.V. Open access under the Elsevier OA license. 1. Introduction
Mesial temporal lobe epilepsy with hippocampal sclerosis (TLE-HS)
is a frequent conditionwithin the pharmacoresistant group of epilepsies
classiﬁed as a syndrome with clinical, electroencephalographic, genetic
and immunological features (Berg, 2009; Vezzani et al., 2011). Indica-
tion that TLE-HS is a progressive disease was established after evidence
that initial precipitant incidents (IPI) in childhood was followed by a la-
tent period until onset of spontaneous seizures at later age (Wieser,
2004). The release of inﬂammatory cytokines in mesial structures may
activate mechanisms associated with prolonged epileptic seizure and
neuronal damage (Balosso et al., 2009), and also neurogenesis,
neuroplasticity and synaptic reorganization (Jankowsky and Patterson,
2001; Vezzani et al., 2011).
TNF-α proinﬂammatory cytokine is expressed at low levels in
healthy brain but is rapidly upregulated in glia, neurons and endothelial
cells during seizures (Fabene et al., 2010). Transient transcription of
IL-1β, transforming growth factor beta (TGF-β1) and overexpression
of TNFα and IL-6 after induced status epilepticus in experimentalmodels
(Minami et al., 1991; De Simoni et al., 2000) indicate that activation of
cytokine signaling cascade inﬂuences development of recurrent seizures
and brain tissue remodeling (Lehtimaki et al., 2007; Aronica and Crino,athology, Institute of Biology,
razil. Tel.: +55 21 2629 2305;
s).
vier OA license. 2011; Lehtimaki et al., 2011). Additionally, altered cytokine plasma
levels have been associated with the frequency and severity of temporal
seizures, and also with focal and generalized epilepsy during interictal
period (Lehtimaki et al., 2007; Mlodzikowska-Albrecht et al., 2007;
Alapirtti et al., 2009; Nowak et al., 2011). Such evidences support the hy-
pothesis that dysregulation and/or excessive cytokine production could
induce seizures and lead to neuronal degeneration in susceptible sub-
jects. This work aimed to determine the circulating level of cytokines
(TNFα; IL-1β; IL-6, sTNFR1, TGF-β1 and CCL3/MIP-1α) that inﬂuence in-
ﬂammatory responses predisposing to seizures and/or tissue remodel-
ing in adult central nervous system. In addition we assessed whether
ablation of epileptogenic lesion of TLE patientswith hippocampal sclero-
sis and active pharmacoresistant epilepsy would improve clinical condi-
tion and reduce seizures.
2. Materials and methods
2.1. Patients
This prospective study carried out from October 2009 to December
2010 in theClementino Fraga FilhoUniversityHospital included after ap-
propriate informed consent, 35 patients with chronic TLE (19males and
16 females) attending Neurology and Neurosurgery services at a tertiary
care university medical hospital. The Hospital Medical Research Ethics
Committee and the Brazilian Ministry of Health (CONEP 073-2007)
approved this study that complies with the principles laid down in the
Declaration of Helsinki. Diagnosis and classiﬁcation of mesial temporal
Table 1
Demographic characteristics of patients with intractable TLE.
All patients were under treatment with two or more anticonvulsant medications of car-
bamazepine, phenytoin, oxcarbazepine, and valproic acid. Normal MRI means absence
of structural abnormality of brain.
Characteristics Operateda Non operated
N=10 N=25
Male 6 (60%) 13 (52%)
Female 4 (40%) 12 (48%)
Mean age years (range)a 39.8 (27 to 59) 39.7 (16 to 51)
Mean age of seizures at onset 13 (1 to 35) 12 (1 to 44)
Onset of seizures (n)
≤18 years 3 (30%) 11 (44%)
≥18 years 7 (70%) 14 (56%)
Mean time of disease duration 25.5 (6 to 41) 28 (6 to 50)
Course of epilepsy (n)
b10 years 2 (4 to 8) 3 (2 to 9)
>10 years 8 (10 to 31) 22 (11 to 40)
Frequency of seizures per month (n) 0 6.5 (2 to 12)
3–4 0 4 (16%)
5–8 4 (40%) 19 (76%)
>8 6 (60%) 2 (8%)
History of IPI Present 4 (40%) Present 7 (28%)
Family history of epilepsy (n)
Yes 2 (20%) 8 (32%)
No 8 (80%) 17 (68%)
Abnormal MRI (n) 4 (40%) 7 (28%)
TLE (left) 8 (80%) 19 (76%)
Latency period (median in years) 22.5 (6 to 35) 10 (4 to 14)
Silent period—(median in years) 9.87 (0 to 25) 9.0 (0 to 33)
a Before surgery.
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criteria (Wieser, 2004; Engel, 2006).
Thirty-ﬁve patients with medically intractable TLE and hippocampal
sclerosis were under investigation for surgery. Among them a group of
10 patients with high (6 to 14 seizures by month) seizure frequency
underwent anterior temporal lobe resection and amygdalohippo-
campectomy (OP). Patients investigated for the history of initial precipi-
tant events (IPI) reported febrile seizure as the most frequent event. At
the time of blood collection patients were free from clinical signs of infec-
tion and seizure for at least a week, considering that cytokine production
is upregulated within 24 h from seizure occurrence (Lehtimaki et al.,
2007). Blood samples from OP patients were also collected 48 h before
and 8 weeks after surgery. Reference range of plasma cytokines was
obtained from 42 (28 males, 66.6%) healthy subjects from the blood
transfusion HEMONIT Centre at Fluminense Federal University with age
range 18 to 61 years (36.8±9.56 years). Eligibility of control group was
assessed by detailed questionnaire, and was only included subjects with
no familial history of epilepsy, infectious disease or under use of anti-
inﬂammatory medication.
TLE patients were submitted to a comprehensive investigation
and neurological examination which included at least a 4-day video-
electroencephalogram (video-EEG) recording, magnetic resonance
imaging (MRI), neuropsychological evaluation, and ictal single pho-
ton emission computed tomography (SPECT). Latency period was de-
ﬁned as the interval between initial precipitating event (IPI) and the
ﬁrst reported spontaneous epileptic seizure, and silent period as the
lag-time between the ﬁrst seizure and initial clinical evidence of
pharmacoresistance (Berg, 2009).
Criteria of eligibility included clinical diagnosis of intractable TLE
based on seizure semiology (Luders et al., 1998), ictal video-EEG and
1.5 T MRI of the brain with characteristic image alteration. All patients
were good candidates to surgery because they presented unilateral
ictal register concordant with unilateral sclerotic hippocampus. Exclu-
sion criteria included occurrence of seizures within the last 24 h before
inclusion; concomitant neoplasm; concomitant infectious or inﬂamma-
tory disease; acute severe cerebrovascular disorder; use of immuno-
modulatory drug within the last 6 months and/or pregnancy. Also, it
was not included patients with genetic syndromes, genetic disorders,
cortical dysgenesias, acquired encephalopaties, or autism.
2.2. Surgical procedure
Anterior temporal lobe resection and amygdalohippocampectomy
were performed in 10 patients by a single neurosurgeon thatmade con-
sistent measurements of resection parameters during surgery. After
surgery, patients continued to use the same antiepileptical drugs (car-
bamazepine, phenytoin, oxcarbazepine, valproic acid). No neurological
and/or cognitive deﬁcits were observed following surgery, and postop-
erative MRI revealed no further complications.
2.3. Blood collection and cytokine assays
5 mL blood samples collected at the same time-matched period
(8 a.m. to 10 a.m.) to minimize inﬂuence of circadian rhythm in the
cytokine release were stored at −80 °C and thawed once just prior
cytokine analysis. TNFα, sTNFR1, IL-6, CCL3/MIP-1α and TGF-β1
(R&D-Systems, Minneapolis, MN) and IL-1β (eBioscience, San Diego,
CA) were quantiﬁed in triplicate by commercial enzyme-linked immu-
nosorbent assays (ELISA) according to the manufacturer's instructions.
In 10 patients blood samples were also collected 48 h before and
8 weeks after surgery for comparison of cytokine levels.
2.4. Statistical analysis
Statistical analysis was carried out using the GraphPad Prism soft-
ware (GraphPad Software Inc., San Diego, CA) with tests analyzingdifferences between groups (Mann–Whitney U-test and Wilcoxon
signed rank test), differences between OP and nOP were tested with
unpaired t-test with Welch's correction, one-way ANOVA test with
Dunn's Multiple Comparison test for multiple comparisons and Mann
Whitney paired test for analysis before and after surgery. The signiﬁ-
cance level was set to pb0.05.
3. Results
All patients (n=35) with temporal lobe epilepsy under investiga-
tion for surgery had a characteristic pattern of selective and extensive
hippocampal atrophy (Table 1) and were under treatment with anti-
convulsant polytherapy medication. In order to accurately deﬁne the
epileptogenic focus it was performed a careful and detailed clinical
semiology including a 4-day video-EEG recording, a 1.5 T MRI, and
also single photon emission tomography (SPECT) which indicated that
patients had TLE characterized as unilateral ictal mesial temporal lobe
epilepsy. During the period of the study, 10 patients (OP) with high (6
to 14) seizure frequency that had been submitted to surgery were
seizure-free for more than 6 months whereas 25 patients (nOP) with
similar epidemiology but still under clinical investigation for surgery
maintained high seizure frequency with 6.5 (range 2 to 12) mean epi-
leptic seizure per month. Such result conﬁrms that sclerotic hippocam-
pus is the main source of electrical events that cause spontaneous
epileptic seizures (Spencer, 1998), and emphasize the importance of
pre-operative MRI and SPECT for critical selection of patients regarding
surgical therapy (Jeha et al., 2006; Vale et al., 2012). Moreover clinical
outcomebased on Engel classiﬁcation (Engel, 2006; Vale et al., 2012) in-
dicated that 85% of patients were classiﬁed as Engel Class-Ia and 15%
Engel Class-Ib as favorable parameter of seizure-freedom outcome for
more than 6 months following anterior temporal lobe resection and
amygdalohippocampectomy.
In order to establish a possible association of neuroinﬂammation
with this form of epilepsy, we compared TNFα, IL-1β, IL-6 and CCL3/
MIP-1α plasma levels between TLE patients (n=35) and healthy
subjects (n=42). TLE patients showed (Fig. 1) a ﬁve-fold increase of
Fig. 1. Comparison of cytokines in TLE patients and controls. Results are expressed as mean±SEM concentration of cytokines in the plasma from control subjects (n=42) and TLE
patients (n=35) with extensive hippocampal atrophy and under treatment with anticonvulsant medication.
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of IL-1β (207±22.7 pg/mL; control: 33±4.89 pg/mL); a 4.9 fold increase
of IL-6 (88.34±7.46 pg/mL; control: 17.89±1.02 pg/mL), and also 11.3
fold increase (158.9±29.49 pg/mL; control: 14,02±1.20 pg/mL) in the
levels of CCL3/MIP-1α, a chemoacttractant cytokine to leukocytes, thus
conﬁrming the inﬂammatory characteristics of TLE.
Excessive neuronal activity and production of proinﬂammatory cy-
tokines have been described in brain tissue after seizures (Hulkkonen
et al., 2004). In this context it was important to verify whether surgical
resection of compromised area could change plasma level of proin-
ﬂammatory cytokines in OP patients. In comparison with nOP patients,
it was observed (Fig. 2) a signiﬁcant reduction of TNFα (OP: 149.3±
14.75 pg/mL; nOP: 236.1±25.79 pg/mL), IL-1β (OP: 164.1±26.5 pg/mL;
nOP: 273.7±33.3 pg/mL); CCL3/MIP-1α (OP: 256±53.23 pg/mL; nOP:
76.80 pg/mL±19.17 pg/mL) but IL-6 (OP: 90.29±pg/mL; nOP: 79.74±
8.59 pg/mL), a neuropoietic cytokine with important role promotingFig. 2. Effect of surgery in plasma levels of inﬂammatory cytokines. OP (n=10) patients sub
and amygdalohippocampectomy and non-operated (nOP=25). Results are expressed as maxonal sprouting (Hakkoum et al., 2007). Moreover, repeated analysis
in a group of nOP (n=8) showed maintenance of high cytokine levels,
with no signiﬁcant difference between measurements for IL-1β, IL-6
and MIP-1α (data not shown).
Considering that TNFα effect on seizure threshold depends on
endogenous cytokine level within the brain tissue and the type of
receptor (sTNFR1) signaling (Figiel, 2008), it was important to deter-
mine plasma levels of sTNFR1 receptor. Comparing to control subjects
(Fig. 3) a two-tailed analysis showed a signiﬁcant difference (177.7±
8.43; pb0.021) with TLE patients (253.3±24.83) and nOP (pb0.01),
but no difference between nOP (223.9±50.2) and OP patients
(274±53.7). It was then important to determine the ratio of TNFα
and its cognate soluble TNF type I p55 receptor that inhibits TNF-
alpha activity but contains a cytoplasmic death domain known to in-
duce apoptosis (Wajant et al., 2003). Loss of balance between the
number of ligand bonds of cytokines and the activity of their inhibitorsmitted to surgical resection of epileptogenic lesion by anterior temporal lobe resection
ean±SEM.
Fig. 3. Plasma levels of soluble p55 sTNFR1 and TNFα/TNFR1 ratio. (A) sTNFR plasma
levels in control subjects (n=42) and TLE patients (n=35), unpaired two-tailed t-test
showed signiﬁcant difference pb0.021, and also F-test pb0.0001 comparing variances
between groups; (B) TLE patients (OP n=10) submitted to surgical resection of epilepto-
genic lesion by anterior temporal lobe resection and non-operated (nOP) TLE patients
(n=25), no difference (ns) between OP and nOP (pb0.05); (C) TNFα/TNFR ratio, the un-
paired two-tailed t-test with Welch's correction showed signiﬁcant difference between
control and OP (pb0.0001) and nOP (pb0.009), and also between OP and nOP (pb0.020).
Results are expressed as mean±SEM.
Fig. 4. TGF-β1 plasma levels in controls and TLE patients. TGFβ plasma levels in control
subjects (n=42) and TLE patients (OP, n=10) submitted to surgical resection of epilep-
togenic lesion and non-operated (nOP) TLE patients (n=25). Two-tailed unpaired t-test
with Welch's correction showed signiﬁcant difference (pb0.0001) in plasma levels be-
tween control and TLE patients and Kruskal–Wallis test showed signiﬁcant difference
(pb0.001) between groups but no difference between nOP and OP (pb0.05). Results are
expressed as mean±SEM.
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2001; Veroni et al., 2010). This analysis showed a signiﬁcant difference
(pb0.001) of TNF/sTNFR1 ratio between control group (0.28±0.02)
and OP patients (0.73±0.05; pb0.0001), and also nOP patients (2.20±
0.61; pb0.009). It was further observed by unpaired two-tailed analysis
a signiﬁcant difference between OP and nOP (pb0.020).
Next it was important to determine changes in TGF-β1, a pleiotropic
cytokine with diverse actions including regulation of inﬂammatory
response during chronic neurodegeneration and neuronal reorganiza-
tion (Boche et al., 2006; Wachs et al., 2006). It was observed (Fig. 4) a
signiﬁcant difference (pb0.0001) between control subjects (28.18±
5.26 pg/mL) and TLE patients: OP (244.8±41.28 pg/mL), and nOP
(265.3±78.8 pg/mL), but not (p>0.05) between OP and nOP.
We further compared (Fig. 5) the plasma level of proinﬂammatory
cytokines determined 48 h before (BS) and 8 weeks after (AS) surgery.
It was observed a marked reduction of IL-1β (BS: 235±53.71 pg/mL;
AS:107.5±36.82 pg/mL; p=0.0063); IL-6 (BS: 98.13±9.27 pg/mL; AS:
64.29±6.37 pg/mL; p=0.0039); MIP-1α (BS: 163.9±41.75 pg/mL;
AS: 24.96±3.19 pg/mL; p=0.0003), TNFα (BS: 198.6±27.12; AS:
119.14±14.41; pb0.0258); TNFR1 (BS: 248.1±40.96; AS: 126.5±
13.10; pb0.0381), but no signiﬁcant difference of TNFα/sTNFR1 ratio
(BS: 1.17±0.28; AS: 0.99±0.12) determined before and after surgery.
Conversely, it was observed a signiﬁcant (pb0.0149) increase of TGF-β1
levels between samples collected 48 h before (194.5±11.37 pg/mL)
and 8 weeks after surgery (299.7±37.83 pg/mL).4. Discussion
Temporal lobe epilepsy is characterized by focal seizures arising
from either the neocortex or mesial temporal structures. Current
knowledge from histological analysis of human brain has implicated
an ongoing chronic inﬂammation in the etiopathogenesis of seizures as-
sociatedwith neuronal degeneration and reactive gliosis (Mlodzikowska-
Albrecht et al., 2007). Brain parenchymal cells (microglia, astrocytes,
and neurons), microvascular cerebral endothelial cells and choroid
plexus are known to produce and express cytokine receptors (Aarli,
2000) that may promote neuroinﬂammation, a process characterized
by increased glial activation, pro-inﬂammatory cytokine production, al-
teration of blood–brain-barrier permeability, and leukocyte invasion.
Yet, peripheral blood cytokines can also enter the brain by passive
and/or active transport (Vezzani et al., 2008) thus inﬂuencing the path-
ogenesis of epilepsy as disease-modifying molecules (Bauer et al.,
2009). Evidence that TNF receptors are rapidly upregulated in neurons
during seizures (Vezzani et al., 2008) is a strong indication that epileptic
seizures may trigger abnormal production of pro-inﬂammatory and
proconvulsive cytokines. The present study shows that TLE patients
with chronic and medically intractable TLE with ictal mesial temporal
lobe hippocampal sclerosis exhibit high IL-1β, IL-6, MIP-1α, TNFα,
sTNFR1 and TGF-β1 circulating cytokines in comparison to healthy con-
trol subjects. Furthermore, anterior temporal lobe resection and
amygdalohippocampectomy was capable to abolish seizures, markedly
reduce plasma level of the inﬂammatory cytokines IL-1β, TNFα, CCL3/
MIP-1α butwithmaintenance of increased IL-6 and TGF-β1 production,
both multifunctional cytokines and trophic factors important for pro-
moting neuronal regeneration (Heinrich et al., 2003; Vivien and Ali,
2006; Hakkoum et al., 2007). It is conceivable that reduction of circulat-
ing cytokines with neuroinﬂammatory proﬁle may be used in a long-
term follow-up as an additional tool that may be used as an indication
of favorable outcome after temporal lobe surgery.
TGF-β1 is a prototypic ﬁbrogenic factor active during tissue remodel-
ing andﬁbrosiswith a central role in brain tissue repair controlling neural
stem cell proliferation inﬂuenced by changes within the microenviron-
ment (Flood et al., 2001; Vivien and Ali, 2006; Wachs et al., 2006).
TGF-β1 is also considered an injury-related cytokine associated with al-
teration of permeability and vascular integrity of the blood–brain barrier
Fig. 5. Plasma level of cytokines determined before and after surgery. Plasma level of cytokines determined 48 h before (BS) and 8 weeks after (AS) surgery paired t-test analysis
showed a signiﬁcant reduction of IL-1β (p=0.0063); IL-6 (pb0.0039); MIP-1α (p=0.0003); TNFα (pb0.0258) and sTNFR1 p55 (pb0.0381), but increased TGF-β1 (pb0.0149)
levels 8 weeks after surgery (AS). Results are expressed as mean±SEM.
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albumin, thus resulting in gradual development of hypersynchronous
neuronal epileptiform activity (Cacheaux et al., 2009; Friedman and
Dingledine, 2011). The presence of high TGF-β1 in both groups of TLE
patientsmay reﬂect sustained tissue remodeling as consequence of neu-
ronal damage associated with seizures in non-operated patients and ac-
tive neurogenesis in TLE patients that became seizure-free after surgery.
Besides the neurotrophic effect (Mlodzikowska-Albrecht et al.,
2007; Figiel, 2008), cytokines may also act as mediators of astrogliosis
and neuronal damage associatedwith seizures (Peltola et al., 2000). Ep-
ileptic activity per se is sufﬁcient not only to induce prominent inﬂam-
matory response in the brain tissue but also causes seizure-induced
neuronal damage and survival (Mlodzikowska-Albrecht et al., 2007;
Figiel, 2008). Indeed, TNFα secretion by microglia and sTNFR1 p55
receptor-dependent calcium inﬂux activation cause disturbances in
neurotransmitter systems that induces glutamate-dependent neuronal
death via activation of the N-methyl-D-aspartate (NMDA) thus leading
to clinical seizures (Jara et al., 2007; Mlodzikowska-Albrecht et al.,
2007; Vezzani et al., 2008; Cheng et al., 2010). A good clinical outcome
may be achieved by complete excision of epileptogenic lesion (Krsek et
al., 2007). Indeed the results show that complete excision of epilepto-
genic lesion abolished seizures up to 6 months after surgery and re-
duced nearly two-fold the plasma levels of TNFα, IL-1β, MIP-1α.
Some antiepileptic drugs (carbamazepine, valproic acid) inhibit
activation of the nuclear transcription factor NFkB which is essential
for the production of proinﬂammatory cytokines (Ichiyama et al.,
2000; Mlodzikowska-Albrecht et al., 2007). Since both groups (nOP,
OP) were under similar treatment and did not differ in epidemiologic
characteristics that might inﬂuence cytokine release, the net increase
of inﬂammatory cytokine in nOP patients but not OP patients indicatesthat the most likely origin of such cytokines is the brain tissue, because
surgery markedly reduced cytokine production and abolished seizures
only in TLE patients that had undergone anterior temporal lobe resec-
tion and amygdalohippocampectomy. The present data also indicate
that cytokine levels correlated with seizure frequency and severity
(data not shown), thus supporting the hypothesis that inﬂammation
is more extensive when seizures are associated with cell damage
(Aarli, 2000; Vezzani et al., 2008). Single seizures cause activation of cy-
tokine cascade and associated inﬂammatory signals, whereas recurrent
seizures cause structural changes and promote brain tissue remodeling
(Lehtimaki et al., 2010, 2011). Moreover activated microglia rapidly
upregulates TGF-β1 production and signaling which induces epilepti-
form activity, but may conversely down regulates microglial responses
and minimize brain inﬂammation (Boche et al., 2006; Wachs et al.,
2006; Cacheaux et al., 2009). It is not ruled out that as already proposed
(Lu et al., 2009), sustained production of TGF-β1 in both OP and nOP pa-
tients is modifying the glial–neuron interaction during epileptogenesis
and/or exerting a cytoprotective activity and tissue repair. High produc-
tion of TGF-β1 and IL-6 in both groups indicates a central role in
sustained tissue remodeling (Peltola et al., 2000; Heinrich et al., 2003;
Vivien and Ali, 2006; Hakkoumet al., 2007) associatedwith detrimental
signaling as consequence of neuronal damage associatedwith recurrent
seizures in epileptic tissue (non-operated patients), but conversely due
to activation of newly neuronal–glial circuitry reorganization in pa-
tients that became seizure-free after surgery.
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